phentolamine mesilate
CLINICAL USE
Alpha-adrenoceptor blocker:Hypertensive crisis
DOSE IN NORMAL RENAL FUNCTION
2–5 mg repeated if necessary
PHARMACOKINETICS
Molecular weight                           :377.5 %Protein binding                           :54 %Excreted unchanged in urine     : 13 Volume of distribution (L/kg)       :No datahalf-life – normal/ESRD (hrs)      :19 minutes/– DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function Titrate dose to end point, i.e. lower BP DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unknown dialysability. Dose as in normal renal function HD                     :Unknown dialysability. Dose as in normal renal functionHDF/high flux   :Unknown dialysability. Dose as in normal renal functionCAV/VVHD      :Unknown dialysability. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect Antidepressants: additive hypotensive effect with MAOIs – avoid concomitant useAntihypertensives: enhanced hypotensive effect Diuretics: enhanced hypotensive effect Linezolid: additive hypotensive effect Moxisylyte: possibly severe postural hypotension Vardenafil, sildenafil and tadalafil: enhanced hypotensive effect – avoid concomitant use ADMINISTRATION
Reconstition
– Route
IV Rate of Administration
–Comments
– OTHER INFORMATION
Titrate according to response
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home